Pharmacotherapy of chronic back pain: Are there prospects?
Treatment for chronic back pain (CBP) is a complex therapeutic challenge. The heterogeneity of the disease, different phenotypes of pain, comorbidities, and individual sensitivity to drugs require the use of a broad-spectrum of analgesics with different mechanisms of action. The present review brief...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/784 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023427284402176 |
|---|---|
| author | G. I. Shvartsman A. E. Karateev |
| author_facet | G. I. Shvartsman A. E. Karateev |
| author_sort | G. I. Shvartsman |
| collection | DOAJ |
| description | Treatment for chronic back pain (CBP) is a complex therapeutic challenge. The heterogeneity of the disease, different phenotypes of pain, comorbidities, and individual sensitivity to drugs require the use of a broad-spectrum of analgesics with different mechanisms of action. The present review briefly considers the evidence base of basic pharmacological groups that are used for the treatment of CBP in real clinical practice or in clinical trials: nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, tumor necrosis factor-α (TNF-α) inhibitors, nerve growth factor inhibitors, opioids, antidepressants, and muscle relaxants, as well as antibiotic therapy. It is shown that at the moment there are no existing or promising drugs that are able to completely solve the problem of CBP. Treatment should be initiated with NSAIDs. Although their efficacy in CBP is relatively low; nevertheless, the use of NSAIDs makes it possible to achieve a certain reduction in pain and to create conditions for the successful use of other drug classes and non-drug methods. The benefits of nimesulide that may be deemed to be a first-line drug among NSAIDs are considered in terms of its efficacy, relative safety, and availability. |
| format | Article |
| id | doaj-art-c2172633abb64462ada109243ade0f4a |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2017-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-c2172633abb64462ada109243ade0f4a2025-08-20T03:01:22ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2017-09-0111311212010.14412/1996-7012-2017-3-112-1202057Pharmacotherapy of chronic back pain: Are there prospects?G. I. Shvartsman0A. E. Karateev1I.I. Mechnikov North-West State Medical University, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyTreatment for chronic back pain (CBP) is a complex therapeutic challenge. The heterogeneity of the disease, different phenotypes of pain, comorbidities, and individual sensitivity to drugs require the use of a broad-spectrum of analgesics with different mechanisms of action. The present review briefly considers the evidence base of basic pharmacological groups that are used for the treatment of CBP in real clinical practice or in clinical trials: nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, tumor necrosis factor-α (TNF-α) inhibitors, nerve growth factor inhibitors, opioids, antidepressants, and muscle relaxants, as well as antibiotic therapy. It is shown that at the moment there are no existing or promising drugs that are able to completely solve the problem of CBP. Treatment should be initiated with NSAIDs. Although their efficacy in CBP is relatively low; nevertheless, the use of NSAIDs makes it possible to achieve a certain reduction in pain and to create conditions for the successful use of other drug classes and non-drug methods. The benefits of nimesulide that may be deemed to be a first-line drug among NSAIDs are considered in terms of its efficacy, relative safety, and availability.https://mrj.ima-press.net/mrj/article/view/784chronic back painpharmacotherapynonsteroidal anti-inflammatory drugsglucocorticoidsbiological agentsnerve growth factor inhibitorsopioidsantidepressantsmuscle relaxantsantibiotic therapy |
| spellingShingle | G. I. Shvartsman A. E. Karateev Pharmacotherapy of chronic back pain: Are there prospects? Современная ревматология chronic back pain pharmacotherapy nonsteroidal anti-inflammatory drugs glucocorticoids biological agents nerve growth factor inhibitors opioids antidepressants muscle relaxants antibiotic therapy |
| title | Pharmacotherapy of chronic back pain: Are there prospects? |
| title_full | Pharmacotherapy of chronic back pain: Are there prospects? |
| title_fullStr | Pharmacotherapy of chronic back pain: Are there prospects? |
| title_full_unstemmed | Pharmacotherapy of chronic back pain: Are there prospects? |
| title_short | Pharmacotherapy of chronic back pain: Are there prospects? |
| title_sort | pharmacotherapy of chronic back pain are there prospects |
| topic | chronic back pain pharmacotherapy nonsteroidal anti-inflammatory drugs glucocorticoids biological agents nerve growth factor inhibitors opioids antidepressants muscle relaxants antibiotic therapy |
| url | https://mrj.ima-press.net/mrj/article/view/784 |
| work_keys_str_mv | AT gishvartsman pharmacotherapyofchronicbackpainarethereprospects AT aekarateev pharmacotherapyofchronicbackpainarethereprospects |